<DOC>
	<DOCNO>NCT00060294</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody yttrium Y 90 ibritumomab tiuxetan rituximab locate cancer cell either kill deliver radioactive cancer-killing substance without harm normal cell . PURPOSE : Phase I trial study effectiveness yttrium Y 90 ibritumomab tiuxetan treat patient Waldenstrom 's macroglobulinemia .</brief_summary>
	<brief_title>Yttrium Y 90 Ibritumomab Tiuxetan Treating Patients With Waldenstrom 's Macroglobulinemia</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose yttrium Y 90 ibritumomab tiuxetan patient Waldenstrom 's macroglobulinemia . - Determine , preliminarily , response patient treated drug . OUTLINE : This multicenter , dose-escalation study yttrium Y 90 ibritumomab tiuxetan ( IDEC-Y2B8 ) . Patients receive rituximab IV indium In 111 ibritumomab tiuxetan ( IDEC-In2B8 ) IV 10 minute day 1 . Patients undergo gamma camera scan within 2-24 hour . Approximately 7-14 day IDEC-In2B8 , patient receive rituximab IV IDEC-Y2B8 IV 10 minute . Treatment IDEC-Y2B8 may repeat every 12 week absence unacceptable toxicity achievement maximum cumulative dose . Cohorts 3-6 patient receive escalate dos IDEC-Y2B8 maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose-limiting toxicity . Patients follow every 3 month 4 year . PROJECTED ACCRUAL : A total 3-24 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis Waldenstrom 's macroglobulinemia confirm IgM gammopathy bone marrow biopsy Presence lymphoplasmacytic cell CD20+ plasma cell dyscrasia majority malignant cell Bone marrow involvement 2050 % core needle biopsy least 1.5 cm length Clinical indication initiation treatment , include 1 follow characteristic : Symptoms associate disease ( e.g. , fatigue , asthenia , painful adenopathy ) Anemia IgM great 3 g/L Progression indicate rate IgM rise 0.5 g 6 month No myelodysplastic syndrome profound hypocellularity bone marrow PATIENT CHARACTERISTICS : Age Over 18 Performance status WHO 02 Life expectancy More 3 month Hematopoietic Absolute neutrophil count great 1,500/mm^3 Total Blymphocyte count le 5,000/mm^3 Platelet count great 100,000/mm^3 No hyperviscosity syndrome Hepatic Bilirubin great 1.5 mg/dL Renal Not specify Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 1 year study completion No uncontrolled CNS disease No serious nonmalignant disease would preclude study participation No concurrent active malignancy except controlled skin cancer prostate cancer PRIOR CONCURRENT THERAPY : Biologic therapy More 2 week since prior filgrastim ( GCSF ) sargramostim ( GMCSF ) More 4 month since prior rituximab No prior radioimmunotherapy Chemotherapy No prior highdose chemotherapy ( unless patient prior backup stem cell collection ) More 6 week since prior chemotherapy Endocrine therapy More 4 week since prior corticosteroid Radiotherapy No prior radiotherapy Surgery Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Waldenstr√∂m macroglobulinemia</keyword>
</DOC>